Long-Term Improvements in Glycemia and User-Reported Outcomes Associated with Open-Source Automated Insulin Delivery Systems in Adults with Type 1 Diabetes in the United Kingdom: A Real-World Observational Study

<b><i>Objective:</i></b> To evaluate real-world outcomes in adults with type 1 diabetes initiating open-source automated insulin delivery systems (OS-AID). <b><i>Methods:</i></b> Adults with type 1 diabetes who commenced OS-AID, between May 2016 and April 2021, across 12 centers in the United Kingdom were included. Anonymized clinical data, collected during routine clinical care between December 2019 and November 2023, were submitted to a secure web-based tool within the National Health Service network. Outcomes included change in hemoglobin A1c (HbA1c), sensor glucometrics, diabetes distress score, Gold score (hypoglycemia awareness), user opinion of OS-AID, and event rates (hospital admissions, paramedic callouts, severe hypoglycemia, and adverse events) between baseline and follow-up. <b><i>Results:</i></b> In total, 81 OS-AID users were included (51.9% male; 90.1% White British; mean age 41.4 years; median diabetes duration 25 years [IQR 17-32]). Over a mean follow-up of 1.7 years, HbA1c reduced by 0.8% (9 mmol/mol) (7.3 ± 1.1% vs. 6.5 ± 0.7%; <i>P</i> < 0.001), and the percentage of individuals achieving HbA1c ≤ 7.0% (53 mmol/mol) increased from 48.6% to 75.7% (<i>P</i> < 0.001). Diabetes-related distress score reduced by 0.9 (95% confidence interval [CI] -0.3, -1.5; <i>P</i> = 0.006), and Gold score reduced by 0.7 (95% CI -0.1, -1.3; <i>P</i> = 0.022). The percentage of individuals with impaired hypoglycemia awareness (Gold score ≥4) reduced (27.8% at baseline vs. 8.3% at follow-up; <i>P</i> = 0.039). Of those asked, all participants stated that OS-AID had a positive impact on quality of life. The number of hospital admissions was low. <b><i>Conclusions:</i></b> The use of OS-AID is associated with long-term improvements in HbA1c, hypoglycemia awareness, and diabetes-related distress in type 1 diabetes. These benefits were achieved without increased rates of hospital admissions, diabetic ketoacidosis, or severe hypoglycemia.

Authors

Institutions

Publication Details

Journal
Diabetes Technology & Therapeutics
Published
2025-01-27
DOI
https://doi.org/10.1089/dia.2024.0556
Citations
3
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
3.88

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-Term Improvements in Glycemia and User-Reported Outcomes Associated with Open-Source Automated Insulin Delivery Systems in Adults with Type 1 Diabetes in the United Kingdom: A Real-World Observational Study

Emma G. Wilmot, Sufyan Hussain, Roselle Herring, Buddhike Mendis et al.
3 citations
Diabetes Technology & Therapeutics
Diabetes Management and Research
3.88
article

Long-Term Improvements in Glycemia and User-Reported Outcomes Associated with Open-Source Automated Insulin Delivery Systems in Adults with Type 1 Diabetes in the United Kingdom: A Real-World Observational Study

Emma G. Wilmot, Sufyan Hussain, Roselle Herring, Buddhike Mendis, Alexandros Leonidas Liarakos, Anastasios Gazis, Robert E. J. Ryder, Thomas Crabtree, Neil Black, Rachel Patel, Adele Kennedy
article en
3 citations

Abstract

<b><i>Objective:</i></b> To evaluate real-world outcomes in adults with type 1 diabetes initiating open-source automated insulin delivery systems (OS-AID). <b><i>Methods:</i></b> Adults with type 1 diabetes who commenced OS-AID, between May 2016 and April 2021, across 12 centers in the United Kingdom were included. Anonymized clinical data, collected during routine clinical care between December 2019 and November 2023, were submitted to a secure web-based tool within the National Health Service network. Outcomes included change in hemoglobin A1c (HbA1c), sensor glucometrics, diabetes distress score, Gold score (hypoglycemia awareness), user opinion of OS-AID, and event rates (hospital admissions, paramedic callouts, severe hypoglycemia, and adverse events) between baseline and follow-up. <b><i>Results:</i></b> In total, 81 OS-AID users were included (51.9% male; 90.1% White British; mean age 41.4 years; median diabetes duration 25 years [IQR 17-32]). Over a mean follow-up of 1.7 years, HbA1c reduced by 0.8% (9 mmol/mol) (7.3 ± 1.1% vs. 6.5 ± 0.7%; <i>P</i> < 0.001), and the percentage of individuals achieving HbA1c ≤ 7.0% (53 mmol/mol) increased from 48.6% to 75.7% (<i>P</i> < 0.001). Diabetes-related distress score reduced by 0.9 (95% confidence interval [CI] -0.3, -1.5; <i>P</i> = 0.006), and Gold score reduced by 0.7 (95% CI -0.1, -1.3; <i>P</i> = 0.022). The percentage of individuals with impaired hypoglycemia awareness (Gold score ≥4) reduced (27.8% at baseline vs. 8.3% at follow-up; <i>P</i> = 0.039). Of those asked, all participants stated that OS-AID had a positive impact on quality of life. The number of hospital admissions was low. <b><i>Conclusions:</i></b> The use of OS-AID is associated with long-term improvements in HbA1c, hypoglycemia awareness, and diabetes-related distress in type 1 diabetes. These benefits were achieved without increased rates of hospital admissions, diabetic ketoacidosis, or severe hypoglycemia.

Diabetes Technology & TherapeuticsVol. 27(4)
University of Ulster (GB), University of Nottingham (GB), King's College London (GB), Guy's and St Thomas' NHS Foundation Trust (GB), Royal Derby Hospital (GB), Sandwell & West Birmingham Hospitals NHS Trust (GB), Altnagelvin Area Hospital (GB), Nottingham City Hospital (GB), Northern Health and Social Care Trust (GB), Antrim Area Hospital (GB), Western Health and Social Care Trust (GB), Thomas Foundation (AU), Kings Health Partners (GB), King's College School (GB), Queen's Medical Centre (GB), Royal Surrey NHS Foundation Trust (GB), University Hospitals of Derby and Burton NHS Foundation Trust (GB), Diabetes UK (GB)
Nottingham University Hospitals NHS Trust, University Hospitals Birmingham NHS Foundation Trust, University of Cambridge, King's College London, University of Nottingham, Cambridge University Hospitals
Openalex Percentile: Top 8%
Diabetes Management and Research
3.88
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.